Rockcliffe Labs Launches Canada’s First Venture-Building Platform for Biotechnology and Life Sciences with Mission to Create 100 CompaniesTORONTO, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Rockcliffe Labs Inc. (“Rockcliffe Labs”), a Canadian biotechnology venture creation platform, announces the launch of its first dedicated program designed to transform breakthrough scientific discoveries into scalable companies. This launch establishes Rockcliffe Labs as the first institution of its kind in Canada, with a mandate to create 100 biotechnology and life sciences ventures over the next decade.
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual CongressMedian progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91%
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (
NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology (ESMO) Congress 2025 being held in Berlin (Poster 1644P).
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted by its partner, Shanghai Jeyou Pharmaceutical Co., Ltd. (Jeyou), formerly called Shanghai Jemincare Pharmaceutical Co., Ltd., in a premarket press release and webcast on Monday, October 20, 2025.RAPT will host a webcast conference call accompanied by a slide presentation on Monday, October 20, 2025 at 8:30 a.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.
Arbrest Champions Sustainability with Solid Wood Furniture That Extends the Life of TreesSAN FRANCISCO, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Arbrest, a rising DTC home furnishing brand, today announced the launch of its independent website (www.arbrest.com). Guided by its “Gentle Design” philosophy, Arbrest blends natural materials with modern aesthetics to create furniture that gives homes room to breathe, shift, and settle. The brand’s vision, “Where Nature Rests, Life Finds Its Rhythm,” is to help every household find its own rhythm of living.
Sify Technologies to announce Financial Results for Second Quarter FY 2025-26 on Saturday, October 25, 2025CHENNAI, India, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Sify Technologies Limited (
NASDAQ: SIFY), India’s leading Digital ICT solutions provider with global service capabilities spanning Data Center, Cloud, Networks, Security and Digital services, today announced that it will report its unaudited IFRS financial results for the second quarter ended September 30, 2025 on Saturday, October 25, 2025 before the market opens.
PUBMATIC CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds PubMatic Investors to Contact the Firm Before the October 20th Deadline in the Filed Class Action LawsuitBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PubMatic (PUBM) To Contact Him Directly To Discuss Their Options
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates GES, AL, HNI on Behalf of ShareholdersNEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ODP, SCS, MESA on Behalf of ShareholdersNEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TIPT, SMLR, FITB on Behalf of ShareholdersNEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
FLY-E CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Fly-E Investors to Contact the Firm Before the November 7th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Fly-E (FLYE)To Contact Him Directly To Discuss Their Options
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates RYN, PCH, ATXS on Behalf of ShareholdersNEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Savara, Inc. Investors to Contact the Firm Before November 7th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE and HI on Behalf of ShareholdersNEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
TRONOX CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Tronox Holdings Investors to Contact the Firm Before November 3rd DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Tronox (TROX) To Contact Him Directly To Discuss Their Options
DOW CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Dow, Inc. to Contact the Firm Before the October 28th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Dow To Contact Him Directly To Discuss Their Options
SEMLER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Semler Scientific Investors to Contact the Firm Before the October 28th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Semler (SMLR) To Contact Him Directly To Discuss Their Options
LIFEMD CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds LifeMD Investors to Contact the Firm Before the October 27th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeMD (LFMD) To Contact Him Directly To Discuss Their Options
NUTEX CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Reminds Nutex Health Investors of the October 21st Deadline for the Filed Class Action LawsuitBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nutex (NUTX) To Contact Him Directly To Discuss Their Options
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung CancerBOSTON, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Precede Biosciences, a company advancing precision medicine through its first-in-class comprehensive epigenomic liquid biopsy platform, today announced the presentation of new data at the European Society for Medical Oncology (ESMO) Congress 2025, held October 17–21, 2025, in Berlin, Germany.
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a higher objective response rate (ORR) and prolonged median progression-free survival (mPFS) across subgroups in patients treated with non-carrier-added (n.c.a) 177Lu-edotreotide (also known as ITM-11 or 177Lu-edotreotide) compared to everolimus from its Phase 3 COMPETE trial in Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Study investigator Jaume Capdevila, MD, PhD, presented the data in an oral presentation at the European Society for Molecular Oncology (ESMO) Congress, held October 17-21, 2025 in Berlin, Germany.
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025SAN FRANCISCO, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced updated data from the Phase 1b/2 study of palazestrant in combination with ribociclib in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. These findings will be presented in a poster session on October 20 at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.
Aeroméxico Announces Filing of Amended Registration Statement for Proposed Global OfferingMEXICO CITY, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Grupo Aeroméxico, S.A.B. de C.V. (“Aeroméxico”) today announced the launch of its global offering (the “Global Offering”), consisting of 11,727,325 American Depositary Shares (“ADSs”) in the United States and 27,463,590 common shares in Mexico. Each ADS represents 10 common shares of Aeroméxico.
StoneX Expands Wealth Management Offering for Latin American ClientsNEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- StoneX Group Inc. (
NASDAQ: SNEX), a global financial services firm connecting clients to the markets across asset classes and geographies, today announced it has completed its acquisition of Intercam Advisors, Inc. and Intercam Securities, Inc., —U.S.-based firms providing brokerage and investment advisory services to Latin American clients.
Kirby McInerney LLP Reminds Baxter International, Inc. Investors of Class Action Filing and Encourages Investors to Contact the FirmNEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Baxter International, Inc. (“Baxter” or the “Company”) (
NYSE:BAX) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
UniFirst Announces Revised Segment ReportingWILMINGTON, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Beginning with the fourth quarter and year ended August 30, 2025, UniFirst Corporation (the “Company,” “we,” or “our”) will be changing the structure of its reporting organization, which will result in corresponding changes to the Company’s financial operating and reportable segments.
TROX Lead Plaintiff Deadline (11/3/25) Reminder: Tronox Holdings PLC Investors Should Contact Robbins LLP for Information About the Class Action LawsuitSAN DIEGO, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Tronox Holdings PLC (
NYSE: TROX) common stock between February 12, 2025 and July 25, 2025. Tronox operates titanium-bearing mineral sand mines and processes them to produce titanium dioxide (TiO2) products. The complaint alleges that Tronox failed to disclose the truth about its business prospects.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (
NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 62,790 shares of Iovance’s common stock to nine new, non-executive employees.
PyroGenesis Announces Repricing and Extension to Term of WarrantsMONTREAL, Oct. 17, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in innovating for ultra-high temperature processes and engineering, and a technology provider to heavy industry & defense, announces today that up to 1,581,250 common share purchase warrants (the “Warrants”) will be amended.
CCH Holdings Ltd Announces Full Exercise of Over-Allotment OptionBUKIT MERTAJAM, MALAYSIA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CCH Holdings Ltd (the “Company”), a Malaysia-based specialty hotpot restaurant chain, today announced that the underwriters of its previously announced initial public offering (the “Offering”), which closed on October 6, 2025, have exercised their over-allotment option (the “Over-Allotment Option”) in full to purchase an additional 187,500 ordinary shares at the public offering price of US$4.00 per ordinary share resulting in additional gross proceeds of US$750,000, before deducting the estimated underwriting discounts and commissions, non-accountable expense allowance, and estimated offering expenses payable by the Company. After giving effect to the full exercise of the Over-Allotment Option, the total number of ordinary shares sold by the Company in the Offering increased to 1,437,500 ordinary shares and the gross proceeds increased to US$5,750,000, before deducting the estimated underwriting discounts and commissions, non-accountable expense allowance, and estimated offering expenses payable by the Company. The closing of the exercise of the Over-Allotment Option occurred on October 17, 2025. The Company’s ordinary shares began trading on the Nasdaq Capital Market under the symbol “CCHH” on October 3, 2025.
Rackspace Technology to Announce Third Quarter 2025 Earnings on November 6th, 2025SAN ANTONIO, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Rackspace Technology® (
NASDAQ: RXT) a leading end-to-end hybrid cloud and AI solutions company, today announced that it will release its third quarter 2025 financial results after the market closes on Thursday, November 6th, 2025. Gajen Kandiah, Chief Executive Officer, and Mark Marino, Chief Financial Officer, will host a conference call on the day of the release (November 6, 2025) at 5:00 PM ET to discuss the Company’s financial results.
Rivalry Closes Second Tranche of Private PlacementTORONTO, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Rivalry Corp. (the “Company” or “Rivalry”) (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), the leading sportsbook and iGaming operator for digital-first players, today announces that it has closed the second tranche of its non-brokered private placement (the “Private Placement”) previously announced on September 29, 2025. The Company issued 27,600,000 units (“Units”) at a price of C$0.05 per Unit, for gross proceeds of C$1,380,000. Each Unit consists of one (1) subordinate voting share in the capital of the Company (each, a "SV Share") and one (1) SV Share purchase warrant (each, a "Warrant"). Each Warrant is exercisable into one (1) SV Share (each, a "Warrant Share") at a price of C$0.10 per Warrant Share until October 8, 2027. The SV Shares, Warrants and Warrant Shares are subject to a four-month statutory hold period, in accordance with applicable securities legislation. The Company intends to use the proceeds from the Private Placement for corporate development and general working capital purposes.
Onex Canada Asset Management Inc. Announces Termination of Onex Global Equity FundTORONTO, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Onex Canada Asset Management Inc. (the “Manager”) today announced it intends to terminate Onex Global Equity Fund (formerly, Onex International Fund) (the “Fund”) on or about December 29, 2025.
Gyrodyne Announces Agreement with Star Equity FundAgrees to Board Size Reduction and Certain Director Compensation Limitations; Star Equity Withdraws Nominations
Credicorp Ltd.: Credicorp’s “3Q25 quiet period”Lima, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Lima, PERU, October 17th, 2025 - Credicorp Ltd. (“Credicorp”) (NYSE: BAP | BVL: BAP) announces that in accordance with its corporate disclosure policies and to prevent any leaks of financial results and ensure fairness, the Company will start the quiet period for 3Q25’s earnings release on October 30th. This period will end on the date of the release, November 13th. During the quiet period, the Company will not disclose any financial information, comment on financial results, or respond to related questions.
VALUE LINE, INC. DECLARES A QUARTERLY CASH DIVIDEND OF $0.325 PER COMMON SHARENEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Value Line, Inc. (
NASDAQ: VALU) announced today that its Board of Directors declared on October 17, 2025 a quarterly cash dividend of $0.325 per common share, payable on November 10, 2025, to stockholders of record on October 27, 2025. The Company has 9,405,828 shares of common stock outstanding as of October 17, 2025.
Ferrellgas, L.P. Announces Pricing of Senior Notes OfferingLIBERTY, Mo., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Ferrellgas, L.P. (the “Company”) and its wholly-owned subsidiary Ferrellgas Finance Corp. (together with the Company, the “Issuers”) announced today that the Issuers priced an offering of $650.0 million aggregate principal amount of 9.250% senior notes due 2031 (the “Notes”) at an offering price equal to 100% of the principal thereof. The offering of the Notes is expected to close on or about October 27, 2025, subject to customary closing conditions.
4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on October 14, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 25,450 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it will present new preclinical safety and translational data for JADE101, its lead investigational candidate for immunoglobulin A nephropathy (IgAN), during two poster sessions at the American Society of Nephrology (ASN) Kidney Week 2025, taking place November 5–9 in Houston, Texas.
MotorTrend Reveals the 2026 Car of the Year with YourUpdateTVMotorTrend Head of Editorial Ed Loh Shares Exclusive Insights on This Year’s Winner: the Volkswagen Golf GTI and R
BROAD ARROW’S WYNN LAS VEGAS AUCTION FEATURES SOUGHT-AFTER CARS FOR EVERY COLLECTOR’S TASTECOMPLETE DIGITAL CATALOG FOR OCTOBER 31 AUCTION NOW LIVE | INAUGURAL SALE LED BY BUGATTI VEYRON EB 16.4 COUPE, MERCEDES-BENZ 300 SL ROADSTER, AND A HOST OF MODERN COLLECTIBLES
Lexitas Expands Access to Deposition Insights+ Platform for All ClientsAdmissions, Contradictions, and Intelligent AI Assistant Now Accessible Directly From Each Deposition Insights™ Summary
UMKC Launches Record-Breaking Campaign to Transform the FutureBlue & Bold aims to empower students, advance research and elevate communities
Desalination and Reuse Market on the Cusp of the Biggest Boom in Its History, According to the Latest IDRA Desalination and Reuse Handbook 2025–2026OXFORD, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Installed desalination capacity has grown by 40% since 2020, while global water reuse capacity has surged by 52% over the same period, according to findings from the newly released IDRA Desalination & Reuse Handbook 2025–2026.
Sify Infinit Spaces files Draft Red Herring Prospectus in IndiaCHENNAI, India, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sify Infinit Spaces Limited (“SISL”), a wholly owned subsidiary of Sify Technologies Limited (“Sify”), publicly filed a draft red herring prospectus on October 17, 2025 with the Securities and Exchange Board of India, BSE Limited, and the National Stock Exchange of India Limited, in connection with its proposed Initial Public Offering (IPO) of equity shares of face value ₹10 each (“Equity Shares”).
Interpublic Announces Timing for Release of Third Quarter 2025 ResultsNew York, NY, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Interpublic Group (
NYSE: IPG) today announced that it expects to file its quarterly report on Form 10-Q for the quarter ended September 30, 2025 with the U.S. Securities and Exchange Commission with its third quarter 2025 financial results on or before November 10, 2025.
RegEd Recognized in InvestmentNews 5-Star Technology Awards for Innovation in Wealth Management SolutionsThe industry leader’s AI-Powered Advertising Review solution earns distinction for advancing marketing compliance through automation and continuous innovation
Five Star Bancorp Declares Third Quarter Cash DividendRANCHO CORDOVA, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Five Star Bancorp (Nasdaq: FSBC) (“Five Star” or the “Company”), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank (the "Bank"), announced today the declaration of a cash dividend of $0.20 per share on the Company’s voting common stock. The dividend is expected to be paid on November 10, 2025, to shareholders of record as of November 3, 2025.
Transaction in Own SharesTransaction in Own Shares
AI Disruption Arrives in Asset Management: Sagehood’s Agentic Index Surges 38% YTD, Outpacing Hedge FundsSAN FRANCISCO, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sagehood.ai announced live production results for its Agentic AI Index, delivering an outstanding 38% year-to-date return through October 4, 2025 — outperforming most asset managers and hedge funds globally.
GSR IV Acquisition Corp. Announces the Separate Trading of its Shares of Class A Ordinary Shares and Commencing October 20, 2025New York, NY, Oct. 17, 2025 (GLOBE NEWSWIRE) -- GSR IV Acquisition Corp. (“GSRF” or the “Company”) announced today that, commencing October 20, 2025, holders of the units sold in the Company’s initial public offering of 23,000,000 units, which included 3,000,000 units issued upon the full exercise of the underwriter’s over-allotment option (“Units”), may elect to separately trade the Company’s Class A Ordinary Shares (“Class A Ordinary Shares”) and Rights (Rights”) included in the Units. Each Unit consists of one Class A Ordinary Share and one-seventh (1/7th) of one Right, with each whole right entitling the holder thereof to receive one Class A Ordinary Share upon the consummation of an initial business combination. No fractional rights will be issued upon separation of the units and only whole rights will trade. The Class A Ordinary Shares and Rights that are separated will trade on Nasdaq Global Market (“Nasdaq”) under the symbols “GSRF” and “GSRFR,” respectively. Those units not separated will continue to trade on Nasdaq under the symbol “GSRFU.” Holders of units will need to have their brokers contact Odyssey Transfer and Trust Company, the Company’s transfer agent, in order to separate the units into Class A Ordinary Shares and Rights.
National Civil Rights Museum Celebrates Freedom Award Honorees, Voting Rights Anniversary, and Announces Expansion of The Legacy ExperienceMemphis, TN, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The National Civil Rights Museum at the Lorraine Motel celebrated courage, compassion, and leadership at its 34th Annual Freedom Award ceremony, honoring three transformative figures whose work continues to shape the modern struggle for justice and equality.
Higher Education’s Compact with America: Shared Principles for the Common GoodWashington, DC, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The following statement, issued jointly by the American Association of Colleges and Universities and the Phi Beta Kappa Society, was developed in collaboration with college and university presidents and other educational leaders across the country.
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.CALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Eavor Technologies Inc. is pleased to announce the appointment of Mark Fitzgerald as its new President and Chief Executive Officer, effective October 20, 2025.
Azurity Pharmaceuticals Announces the FDA Approval of Ferabright<sup>TM</sup> (ferumoxytol injection), the First and Only Iron-Based Contrast Agent Indicated for Magnetic Resonance Imaging of the BrainWoburn, MA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the first and only iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier.1
Flywire to Announce Third Quarter 2025 Results on November 4, 2025BOSTON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Today, Flywire Corporation (Flywire) (Nasdaq: FLYW), a global payments enablement and software company, announced that its third-quarter financial results will be released after market close on Tuesday, November 4, 2025. Flywire will host a conference call to discuss its third-quarter financial results at 5:00 pm ET the same day. Hosting the call will be Mike Massaro, CEO, Rob Orgel, President and COO, and Cosmin Pitigoi, CFO.
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement- Amendment includes finalized cash amount and updated CVR terms for tender offer
Wake Radiology Grows Breast Imaging Section with Five New Hires; Launches "We See the Difference" Campaign for Breast Cancer Awareness MonthRaleigh, N.C., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Wake Radiology UNC Health Rex, the largest outpatient imaging provider in the Triangle, today announced the continued expansion of its breast imaging section with the addition of five new board-certified radiologists over the past year. The radiologists join the practice at a time when the demand for breast imaging is anticipated to grow, as a larger segment of the population reaches the recommended age of 40, the age at which the American College of Radiology and the Society of Breast Imaging advise women to begin annual screening mammograms.
